T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Breast Cancer Research

Table 3 Multivariate Cox regression of lymphocyte-specific kinase metagene and standard parameters among estrogen receptor-positive HER2-positive tumors

Parameter		n ₁ ^a	n ₂ ^a	P value^b	Hazard ratio	95% confidence interval
Lymphocyte-specific kinase metagene	Low vs. high	21	16	0.011	4.17	1.38 to 12.6
Lymph node status	LNN vs. N1	24	13	0.438	0.69	0.27 to 1.77
Age	>50 years vs. ≤ 50 years	18	19	0.558	1.38	0.47 to 4.09
Pathological grading	Poor vs. well/intermediate	19	18	0.097	2.27	0.86 to 5.99
Tumor size	>2 cm vs. ≤ 2 cm	15	22	0.405	1.63	0.52 to 5.12

^aComplete information on all parameters was available for 37 estrogen receptor-positive human epidermal growth factor receptor 2 (HER2)-positive samples. ^bSignificant values presented in bold.

ISSN: 1465-542X